“Context around patient-identified affordability and access challenges is really critical,” began Karin Hoelzer, DVM, PhD, Senior Director, Patient Advocacy during the Biotechnology Innovation Organization’s […]
Affordability and Access: Why patient perspectives matter Read More »
For people living with psoriatic disease, treatment innovation has advanced dramatically. Yet too many patients remain undiagnosed, untreated, or undertreated. The National Psoriasis Foundation
Connecting more patients with psoriasis to the care they need Read More »
2026 was a busy year on the state level. Whether it was the expected healthcare policy priorities or newer ones, there was plenty to
Mid-year review: State-level legislative action impacting biotech Read More »
When it comes to fighting cancer, time is of the essence. But far too often, utilization management (UM) practices such as prior authorization and
CancerCare project highlights barriers to patient access Read More »
On Tuesday July 28, the Arkansas State Board of Pharmacy suspended enforcement of a 2025 Arkansas law, Act 630, two months after a federal
Following court decision, Arkansas will not enforce Act 630 on drug distribution Read More »
“CAR-T cell therapies are remarkable drugs and are the gold standard for patients,” said Rachel Haurwitz, PhD, President & CEO of Caribou Biosciences. These
BIO 2026: Realizing the promise of CAR-T cell therapies Read More »
While the U.S. Food and Drug Administration (FDA) has faced significant change in recent years, industry leaders and agency officials alike say there are
BIO 2026: FDA leaders discuss restoring workforce, institutional knowledge Read More »
Experts at the BIO International Convention examine the growth of the 340B drug pricing program, duplicate discounts, patient access, and calls for greater transparency.
BIO 2026: 340B faces growing calls for transparency, patient-focused reform Read More »
What started as a conversation, in a bar, written on a napkin in 1976, between biochemist Dr. Herbert W. Boyer and investor Robert A.
After 50 years of biotech, can AI help answer the next impossible question? Read More »
Industry, academic, and policy leaders at BIO 2026 discussed how federal research funding, private investment, and public-private partnerships can strengthen the U.S. biopharma ecosystem
